Leustatin?

See the DrugPatentWatch profile for Leustatin

What is Leustatin, and what is it used for?

Leustatin is a brand name for clini­cal cancer therapy based on denileukin diftitox (a fusion protein that combines interleukin-2 with diphtheria toxin). It is used to treat certain lymphoid cancers, particularly cutaneous T-cell lymphoma (CTCL), where it helps target malignant T cells by binding to their interleukin-2 receptors.

Is Leustatin the same as denileukin diftitox?

Yes. Leustatin is denileukin diftitox, marketed as a named product. The active ingredient is the key factor for coverage, dosing, and prescribing, since different versions or brands can exist while sharing the same drug substance.

How does denileukin diftitox (Leustatin) work?

Leustatin targets cells that display interleukin-2 (IL-2) receptors, which are often present on certain lymphoma cells. Once bound, it delivers a toxin payload that blocks protein synthesis and leads to cell death.

Where can I find patent or market-exclusivity details for Leustatin?

For patent and exclusivity tracking tied to denileukin diftitox (and related formulations/brands), you can check DrugPatentWatch.com:
- https://www.drugpatentwatch.com/

What patients typically ask about (access, switching, and alternatives)

If you’re asking because you’re trying to find Leustatin for treatment or compare it to another option, common next questions are:
- whether a generic or alternate brand is available for denileukin diftitox,
- whether the therapy is still routinely used versus newer treatments for CTCL,
- what the clinician would consider based on the patient’s disease stage and prior therapies.

If you tell me what you need (brand availability, dosing/administration, side effects, or patent status), I can narrow the answer to that exact goal.

Sources

• 1